JP2022542321A5 - - Google Patents
Info
- Publication number
- JP2022542321A5 JP2022542321A5 JP2022506145A JP2022506145A JP2022542321A5 JP 2022542321 A5 JP2022542321 A5 JP 2022542321A5 JP 2022506145 A JP2022506145 A JP 2022506145A JP 2022506145 A JP2022506145 A JP 2022506145A JP 2022542321 A5 JP2022542321 A5 JP 2022542321A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- cell composition
- tumor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025105888A JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880044P | 2019-07-29 | 2019-07-29 | |
| US62/880,044 | 2019-07-29 | ||
| US201962892779P | 2019-08-28 | 2019-08-28 | |
| US62/892,779 | 2019-08-28 | ||
| US202062960507P | 2020-01-13 | 2020-01-13 | |
| US62/960,507 | 2020-01-13 | ||
| PCT/US2020/044117 WO2021021963A1 (en) | 2019-07-29 | 2020-07-29 | Nk cell composition and preparations for immunotherapy and methods for their production |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025105888A Division JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542321A JP2022542321A (ja) | 2022-09-30 |
| JP2022542321A5 true JP2022542321A5 (https=) | 2023-08-07 |
Family
ID=74228666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506145A Withdrawn JP2022542321A (ja) | 2019-07-29 | 2020-07-29 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
| JP2025105888A Pending JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025105888A Pending JP2025156345A (ja) | 2019-07-29 | 2025-06-23 | 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220275334A1 (https=) |
| EP (1) | EP4004193A4 (https=) |
| JP (2) | JP2022542321A (https=) |
| KR (1) | KR20220038450A (https=) |
| CN (1) | CN114466924A (https=) |
| AU (1) | AU2020321953A1 (https=) |
| CA (1) | CA3145510A1 (https=) |
| IL (1) | IL290080A (https=) |
| MX (1) | MX2022001257A (https=) |
| WO (1) | WO2021021963A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7335001B2 (ja) * | 2019-01-18 | 2023-08-29 | アセポディア バイオテクノロジーズ リミテッド | 新規ｃｄ１６＋ナチュラルキラーおよびｃｄ１６＋ナチュラルキラー細胞の培養方法 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP4127188A4 (en) * | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| CN113402620B (zh) * | 2021-07-30 | 2021-12-10 | 中山大学 | 细胞因子联合嵌合抗原受体的融合蛋白及其应用 |
| US20240335472A1 (en) * | 2021-08-10 | 2024-10-10 | Gamida Cell Ltd. | Anti-her2 car nk cells, methods of their production and uses thereof |
| WO2023086642A2 (en) * | 2021-11-15 | 2023-05-19 | City Of Hope | Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy |
| CN114891744B (zh) * | 2022-07-13 | 2022-10-25 | 山东省齐鲁干细胞工程有限公司 | 一种冷冻脐带血nk细胞体外扩增方法 |
| WO2024047368A1 (en) * | 2022-09-02 | 2024-03-07 | Imperial College Innovations Limited | Natural killer cells |
| WO2024113294A1 (zh) * | 2022-12-01 | 2024-06-06 | 血霁生物科技(上海)有限公司 | 一种分化nk细胞的方法、培养基及其应用 |
| CN115927180A (zh) * | 2022-12-01 | 2023-04-07 | 血霁生物科技(上海)有限公司 | 一种分化nk细胞的方法、培养基及其应用 |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
| CN116983409B (zh) * | 2023-07-17 | 2025-11-14 | 中国检验检疫科学研究院 | 一种抑制寨卡病毒的方法及其应用 |
| CN118853562B (zh) * | 2024-07-11 | 2025-08-29 | 中国科学院广州生物医药与健康研究院 | 一种靶向cd19的car-nk细胞及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2795627C (en) * | 2010-04-09 | 2023-03-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| EA201890960A1 (ru) * | 2015-10-15 | 2018-10-31 | Селулэрити, Инк. | Натуральные киллеры и клетки ilc3 и их применение |
| WO2018208702A1 (en) * | 2017-05-09 | 2018-11-15 | Saint Louis University | Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes |
-
2020
- 2020-07-29 JP JP2022506145A patent/JP2022542321A/ja not_active Withdrawn
- 2020-07-29 CN CN202080067440.2A patent/CN114466924A/zh active Pending
- 2020-07-29 CA CA3145510A patent/CA3145510A1/en active Pending
- 2020-07-29 US US17/631,035 patent/US20220275334A1/en active Pending
- 2020-07-29 EP EP20848443.6A patent/EP4004193A4/en active Pending
- 2020-07-29 KR KR1020227006075A patent/KR20220038450A/ko active Pending
- 2020-07-29 WO PCT/US2020/044117 patent/WO2021021963A1/en not_active Ceased
- 2020-07-29 MX MX2022001257A patent/MX2022001257A/es unknown
- 2020-07-29 AU AU2020321953A patent/AU2020321953A1/en active Pending
-
2022
- 2022-01-24 IL IL290080A patent/IL290080A/en unknown
-
2025
- 2025-06-23 JP JP2025105888A patent/JP2025156345A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542321A5 (https=) | ||
| Hu et al. | Natural killer cell-based immunotherapy for cancer: advances and prospects | |
| Childs et al. | Bringing natural killer cells to the clinic: ex vivo manipulation | |
| Dianat‐Moghadam et al. | Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells | |
| US20220378911A1 (en) | Use of Triplex CMV Vaccine in CAR T Cell Therapy | |
| US20200297763A1 (en) | Pluripotent stem cell-derived macrophage capable of targeting tumor cells and preparation method thereof | |
| Zhu et al. | Concise review: human pluripotent stem cells to produce cell-based cancer immunotherapy | |
| Shook et al. | Natural killer cell engineering for cellular therapy of cancer | |
| Mazza et al. | Prospects for development of induced pluripotent stem cell-derived CAR-targeted immunotherapies | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| US20220056411A1 (en) | Methods for isolating cd8+ selected t cells | |
| US20230124097A1 (en) | Engineering stem cell t cells with multiple t cell receptors | |
| US20250129333A1 (en) | RIC cell and preparation method therefor and use thereof | |
| Sahin et al. | Natural killer cell-mediated cellular therapy of hematological malignancies | |
| US20240240148A1 (en) | Engineering stem cells for allogenic car t cell therapies | |
| US20250090581A1 (en) | Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use | |
| KR20250099777A (ko) | 전 세계, 민족 또는 질환 특이적 인구를 포괄하는 동종이계 세포 치료를 위한 면역 적합 세포 | |
| JP2024517968A (ja) | 幹細胞からの操作されたｔ細胞の産生 | |
| Kühnel et al. | Engineered Natural Killer Cell Lines and Their Application for Cancer Immunotherapy | |
| WO2026052061A1 (en) | Adoptive cell compositions | |
| US20240415885A1 (en) | Method for the generation of genetically modified NK cells | |
| WO2025130895A1 (zh) | 一种免疫细胞的制备方法及其用途 | |
| KR20250087602A (ko) | 만능 세포에서 유래된 자연살해세포 계통 | |
| CN120344654A (zh) | 改造的自然杀伤细胞和相关方法 | |
| JP2023504196A5 (https=) |